<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405210</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-ONCO 06-003</org_study_id>
    <secondary_id>BAY 43-9006/12180</secondary_id>
    <nct_id>NCT00405210</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer</brief_title>
  <official_title>Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the most effective dose of BAy 46-9003 associated to&#xD;
      taxotere for first-line treatment of patient with prostatic cancer.&#xD;
&#xD;
      BAY 43-9006 (SORAFENIB) is a novel dual-action Raf kinase and VEGFR inhibitor, which is&#xD;
      orally available and has a favorable safety profile in patients with advanced solid tumors.&#xD;
      This, together with the antitumor activity observed after treatment with BAY 43-9006&#xD;
      (SORAFENIB), provides a rationale for further evaluation in patients with advanced cancer.&#xD;
      The recommended dose of BAY 43-9006 (SORAFENIB) for future studies is 400 mg bid as a&#xD;
      continuous dosing schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study propose to treat patients with metastatic and hormone-refractory prostatic cancer&#xD;
      in first intention. There is no limits of age from 18 years old. A new inhibitor of&#xD;
      angiogenesis (Sorafenib) is associated to the standard treatment in this type of pathology.&#xD;
&#xD;
      Patients have to demonstrate radiologically a disease progression and also a progression&#xD;
      based on increase of psa level.&#xD;
&#xD;
      The main objective is to Determine the recommended dose of BAY 43-9006 in combination with&#xD;
      docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients&#xD;
      with metastatic hormone-refractory prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the recommended dose of BAY 43-9006 (SORAFENIB) in combination with docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients with metastatic hormone refractory prostate cancer.</measure>
    <time_frame>after the first 24 patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics and pharmacodynamics of BAY43-9006 in combination with docetaxel*</measure>
    <time_frame>after the first 24 patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in patients with measurable disease</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response duration</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression (=time between treatment start and PSA progression)</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression after the last dose of docetaxel in patients with no progression after stopping docetaxel (= time between the last dose of docetaxel and PSA progression)</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event progression-free survival</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Primary Disease</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib (200 or 400mg bid) and taxotere iv</intervention_name>
    <description>200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles</description>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to beginning protocol specific procedures.&#xD;
&#xD;
          -  18 years&#xD;
&#xD;
          -  Radiologically proven presence of metastases&#xD;
&#xD;
          -  Histologically/cytologically proven prostate adenocarcinoma.&#xD;
&#xD;
          -  Biochemically evaluable disease&#xD;
&#xD;
          -  Patients must have received prior hormonal therapy as defined below:&#xD;
&#xD;
               -  Castration by orchiectomy and/or LHRH agonists with or without&#xD;
&#xD;
               -  Antiandrogens&#xD;
&#xD;
               -  Other hormonal agents (e.g., ketoconazole, ...)&#xD;
&#xD;
          -  The testosterone level should be &lt; 50 ng/dl (10) documented disease progression&#xD;
             defined by PSA increase. Patients must have a value of at least 5 ng/ml in addition to&#xD;
             increasing PSA to be eligible.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Normal cardiac function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy except estramustine phosphate.&#xD;
&#xD;
          -  Prior isotope therapy (e.g., strontium, samarium).&#xD;
&#xD;
          -  Prior radiotherapy to &gt;25% of bone marrow&#xD;
&#xD;
          -  Prior therapy with anti-VEGF therapy&#xD;
&#xD;
          -  Prior malignancy except the following: adequately treated basal cell or squamous cell&#xD;
             skin cancer, or any other cancer from which the patient has been disease-free for &gt;5&#xD;
             years.&#xD;
&#xD;
          -  History or presence of central nervous system (CNS) disease (i.e. primary brain tumor,&#xD;
             malignant seizures, CNS metastases or carcinomatous meningitis)&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy&#xD;
&#xD;
          -  Other serious illness or medical condition the use of corticosteroids.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational drug within 30 days prior to study screening.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of BAY 9006.&#xD;
&#xD;
          -  Major surgery with 4 weeks of study entry&#xD;
&#xD;
          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study entry&#xD;
&#xD;
          -  Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry&#xD;
&#xD;
          -  Treatment with any other anti-cancer therapy (except LHRH agonists) including any&#xD;
             prescribed compounds and/or OTC products for the treatment of prostate cancer must be&#xD;
             stopped.&#xD;
&#xD;
          -  Treatment with drugs that are metabolized by the cytochrome P450 system (i.e warfarin&#xD;
             sodium,…)&#xD;
&#xD;
          -  Treatment with systemic corticosteroids used for reasons other than specified by the&#xD;
             protocol must be stopped.&#xD;
&#xD;
          -  Biphosphonates could not be initiated after inclusion into the protocol. At inclusion,&#xD;
             patients receiving biphosphonates with a PSA progression could continue&#xD;
             biphosphonates.&#xD;
&#xD;
          -  Patients with reproductive potential not employing an effective method of birth&#xD;
             control. Barrier contraceptives must be used throughout the trial.&#xD;
&#xD;
          -  Inadequate recovery from previous surgery, radiation, chemo-, biologic or&#xD;
             immunotherapy&#xD;
&#xD;
          -  Patients who have known hypersensitivity to the study medication&#xD;
&#xD;
          -  Substance abuse, medical social, psychological conditions that may interfere with the&#xD;
             subject's participation in the study or evaluation of study results&#xD;
&#xD;
          -  Patients unable to sallow oral medications.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal H Machiels, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Cliniques Universitaires St Luc -UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Pierre</name>
      <address>
        <city>Ottignies</city>
        <state>Brabant Wallon</state>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <state>Brussels Capital</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Notre Dame et Reine Fabiola</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universiataire de Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>May 20, 2011</last_update_submitted>
  <last_update_submitted_qc>May 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cliniques universitaires Saint-Luc-Université Catholique de Louvain</name_title>
    <organization>Prof. J-P Machiels</organization>
  </responsible_party>
  <keyword>hormone-resistant</keyword>
  <keyword>metastatic prostatic cancer</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>naïve patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

